Ocular Therapeutix: Interim Data from Phase 1 in Wet AMD

 All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10

CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects

OTX-TKI continued to be generally well tolerated with no drug-related serious adverse events through Month 10

https://www.marketscreener.com/quote/stock/OCULAR-THERAPEUTIX-INC-16917490/news/Ocular-Therapeutix-trade-Announces-Interim-10-month-Data-from-the-Ongoing-U-S-Phase-1-Clinical-Tri-42960967/